Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

被引：8

作者：

Morganti, Stefania ^{[1
,2
,3
,4
,5
,6
]}

Bychkovsky, Brittany L. ^{[1
,2
,3
,7
]}

Poorvu, Philip D. ^{[1
,2
,3
]}

Garrido-Castro, Ana C. ^{[1
,2
,3
,4
]}

Weiss, Anna ^{[8
]}

Block, Caroline C. ^{[1
,2
,3
]}

Partridge, Ann H. ^{[1
,2
,3
]}

Curigliano, Giuseppe

Tung, Nadine M. ^{[3
,9
]}

Lin, Nancy U. ^{[1
,2
,3
]}

Garber, Judy E. ^{[1
,2
,3
]}

Tolaney, Sara M. ^{[1
,2
,3
]}

Lynce, Filipa ^{[1
,2
,3
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Broad Inst MIT & Harvard, Boston, MA USA

[5] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev, Milan, Italy

[6] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[7] Dana Farber Canc Inst, Div Genet & Prevent Program, Boston, MA 02115 USA

[8] Univ Rochester, Dept Surg, Div Surg Oncol, Rochester, NY USA

[9] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA

来源：

ONCOLOGIST | 2023年 / 28卷 / 07期

关键词：

germline BRCA; early breast cancer; olaparib; adjuvant; OlympiA; OPEN-LABEL; HIGH-RISK; CHEMOTHERAPY; MUTATION; CAPECITABINE; SURVIVAL; PEMBROLIZUMAB; ESTROGEN; OUTCOMES; WOMEN;

D O I：

10.1093/oncolo/oyad123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. The benefit was consistent across subgroups, and this regimen is now recommended after chemotherapy for germline BRCA1/2 mutation (gBRCA1/2m) carriers with high-risk, HER2-negative early breast cancer. However, the integration of olaparib in the landscape of agents currently available in the post(neo) adjuvant setting-ie, pembrolizumab, abemaciclib, and capecitabine-is challenging, as there are no data suggesting how to select, sequence, and/or combine these therapeutic approaches. Furthermore, it is unclear how to best identify additional patients who could benefit from adjuvant olaparib beyond the original OlympiA criteria. Since it is unlikely that new clinical trials will answer these questions, recommendations for clinical practice can be made through indirect evidence. In this article, we review available data that could help guide treatment decisions for gBRCA1/2m carriers with high-risk, early-stage breast cancer.

引用

页码：565 / 574

页数：10

共 50 条

[41] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Binghe Xu
Tao Sun
Yanxia Shi
Jiuwei Cui
Yongmei Yin
Quchang Ouyang
Qiang Liu
Qingyuan Zhang
Yiding Chen
Shouman Wang
Xiaojia Wang
Zhongsheng Tong
Yahua Zhong
Jiayu Wang
Min Yan
Xi Yan
Chuan Wang
Jifeng Feng
Xiuli Wang
Gang Hu
Ying Cheng
Ruimin Ge
Zhaoyin Zhu
Wa Zhang
Zhimin Shao
Breast Cancer Research and Treatment, 2023, 197 : 489 - 501
[42] Companion diagnosis by BRACAnalysis CDxTM and therapeutic experience of Olaparib for HER2-negative breast cancer
Kimura, Yuri
Itagaki, Tomoko
Ohara, Masahiro
ANNALS OF ONCOLOGY, 2019, 30
[43] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
Gelmon, Karen A.
Fasching, Peter A.
Couch, Fergus J.
Balmana, Judith
Delaloge, Suzette
Labidi-Galy, Intidhar
Bennett, James
McCutcheon, Susan
Walker, Graham
O'Shaughnessy, Joyce
EUROPEAN JOURNAL OF CANCER, 2021, 152 : 68 - 77
[44] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Robson, M. E.
Tung, N.
Conte, P.
Im, S-A
Senkus, E.
Xu, B.
Masuda, N.
Delaloge, S.
Li, W.
Armstrong, A.
Wu, W.
Goessl, C.
Runswick, S.
Domchek, S. M.
ANNALS OF ONCOLOGY, 2019, 30 (04) : 558 - 566
[45] Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations
Zettler, Christina M.
De Silva, Dilanka L.
Blinder, Victoria S.
Robson, Mark E.
Elkin, Elena B.
JAMA NETWORK OPEN, 2024, 7 (01)
[46] Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis
Dacoregio, Maria Inez
Vilbert, Maysa
Stecca, Carlos
Michelon, Isabella
Castro, Caio
Amir, Eitan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
Sun, Tao
Shi, Yanxia
Cui, Jiuwei
Yin, Yongmei
Ouyang, Quchang
Liu, Qiang
Zhang, Qingyuan
Chen, Yiding
Shao Zhimin
Wang, Shouman
Wang, Xiaojia
Tong, Zhongsheng
Zhong, Yahua
Yan, Min
Yan, Xi
Wang, Chuan
Yang, Haiyuan
Li, Miao
Xiang, Xiao
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
Tung, Nadine
Arun, Banu
Hacker, Michele R.
Hofstatter, Erin
Toppmeyer, Deborah L.
Isakoff, Steven J.
Borges, Virginia F.
Legare, Robert D.
Isaacs, Claudine
Wolff, Antonio C.
Marcom, Paul Kelly
Mayer, Erica L.
Lange, Paulina B.
Goss, Andrew J.
Jenkins, Colby
Krop, Ian E.
Winer, Eric P.
Schnitt, Stuart J.
Garber, Judy E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1539 - +
[49] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
Nozawa, Kazuki
Yoshimura, Akiyo
Iwata, Hiroji
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1439
[50] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
Gelmon, Karen
Walker, Graham P.
Fisher, Graham V.
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →